[Jessica]

NXT-Dx expands its service portfolio with a unique multiplexed immunoassay service, allowing parallel testing of 96 protein markers in 92 samples. The initial assay focuses on cancer markers but additional assays for inflammation and cardiovascular diseases are expected to follow soon.

For little over 2 years, NXT-Dx has been providing state-of-the-art research testing services in epigenetics and transcriptomics to its global customers, from its headquarters in Ghent, Belgium. Now the company is expanding its service portfolio with the addition of its multiplexed immunoassay
service.

"NXT-Dx has been helping researchers in epigenetics and transcriptomics for the past 2 years to achieve their research goals, by offering excellent services combined with great follow-up and support. Now we want extend our portfolio by offering our multiplexed immunoassay service to existing and new customers.". (Maarten Braspenning: Operational and commercial director).

The multiplexed immunoassay allows to quantify 96 protein markers in 92 samples in parallel with no trade-off in data quality, at affordable cost and with minimal input material (as low as 1µL from plasma, serum, fine needle biopsy, tissue lysate, cell lysate, micro-dialysis fluid and synovial fluid).

Maarten Braspenning
NXT-Dx
+32 9 265 02 52
maarten.braspenning@nxt-dx.com